Pancreaze (Pancrelipase) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Pancreaze (Pancrelipase) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing incidence of exocrine pancreatic insufficiency (EPI), the aging population, enhanced treatment options, a rise in pancreatic cancer cases, and the globalization of healthcare services.

The projected growth in the forecast period is driven by the growing prevalence of pancreatic diseases, ongoing research and clinical trials, improved global healthcare access, better healthcare infrastructure, and supportive government initiatives and reimbursement policies. Key trends during this period include advancements in enzyme delivery systems, technological innovations, the integration of digital health solutions, growing partnerships, and the development of enteric-coated formulations.

The increasing number of cystic fibrosis cases is expected to drive the growth of the Pancreaze (pancrelipase) market. Cystic fibrosis is a genetic disorder that affects the lungs, digestive system, and other organs, causing thick, sticky mucus to accumulate, leading to blockages, infections, and impaired organ function. The rise in cystic fibrosis cases is largely due to enhanced awareness, improved diagnostic methods, and the expansion of genetic screening programs, which have led to the identification of more cases, including those that were previously undiagnosed. Pancreaze (pancrelipase) is used to aid digestion in cystic fibrosis by replacing the enzymes that the pancreas fails to produce effectively, improving nutrient absorption and overall nutritional health. For example, in 2023, the Cystic Fibrosis Trust reported a 1.5% increase in the number of registered cystic fibrosis patients in the UK, with the number growing from 11,148 in 2022 to 11,318 in 2023. This rising prevalence of cystic fibrosis is driving the growth of the Pancreaze market.

The increasing incidence of pancreatic conditions is expected to fuel the growth of the pancrelipase market. Pancreatic conditions, including pancreatitis, exocrine pancreatic insufficiency (EPI), pancreatic cancer, and diabetes, can impair the digestive and hormonal functions of the pancreas. The rise in these conditions is largely attributed to factors such as aging populations, higher rates of obesity and diabetes, increased alcohol consumption, smoking, and improvements in diagnostic methods that enable earlier detection. Pancreaze (pancrelipase) is commonly used to manage EPI in conditions such as chronic pancreatitis and pancreatic cancer. It helps restore digestive enzyme levels, improving nutrient absorption and alleviating symptoms such as malnutrition and diarrhea. For instance, Cancer Research UK projected in February 2023 that the number of new pancreatic cancer cases in the UK would increase from approximately 12,500 cases in 2023-2025 to around 16,000 cases by 2038-2040, reflecting a 5% growth in incidence rates. This rise in pancreatic conditions is expected to drive the growth of the pancrelipase market.

A significant trend in the pancreaze (pancrelipase) market is the growing emphasis on clinical evidence to support the drug's efficacy, particularly through clinical trial data. This evidence plays an essential role in securing regulatory approvals, improving patient outcomes, and strengthening a drug's competitive position. For example, in May 2024, Vivus, Inc., a U.S.-based biopharmaceutical company, announced the publication of new clinical trial data that demonstrated the efficacy of Pancreaze (pancrelipase) in stabilizing weight among chemotherapy patients with pancreatic ductal adenocarcinoma (PDAC) who were suffering from cachexia and exocrine pancreatic insufficiency (EPI). The findings also suggested that Pancreaze could help reduce stool frequency and improve stool consistency. The study, which was conducted by researchers at Cedars-Sinai Medical Center and the Samuel Oschin Cancer Center, highlights the growing clinical support for Pancreaze’s use in treating pancreatic conditions.

The key company operating in the pancreaze (pancrelipase) market is AbbVie Inc.

North America was the largest region in the pancreaze (pancrelipase) market in 2024. The regions covered in pancreaze (pancrelipase) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Pancreaze (Pancrelipase) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pancreaze (pancrelipase) is a prescription medication that combines digestive enzymes, such as amylase, lipase, and protease, to aid in the digestion of food. It is mainly prescribed for individuals with pancreatic insufficiency caused by conditions such as cystic fibrosis or chronic pancreatitis.

Pancreaze (pancrelipase) is available in capsule and tablet forms. The capsule version is intended to be swallowed whole and contains powder or granules inside a soft or hard shell, which dissolves in the stomach to release the active enzymes. It is used by individuals across various age groups, including children, adults, and the elderly. The medication is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Its primary applications include treating chronic pancreatitis, cystic fibrosis, and other related conditions.

The pancreaze (pancrelipase) market research report is one of a series of new reports that provides pancreaze (pancrelipase) market statistics, including pancreaze (pancrelipase) industry global market size, regional shares, competitors with a pancreaze (pancrelipase) market share, detailed pancreaze (pancrelipase) market segments, market trends and opportunities, and any further data you may need to thrive in the pancreaze (pancrelipase) industry. This pancreaze (pancrelipase) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreaze (pancrelipase) market consists of sales of pancreaze delayed-release capsules, pancreaze powder, and pancreaze oral pellets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.